



## Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 30, 2024

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.

A live webcast link for the Jefferies Global Healthcare Conference event will be available at <https://investors.werewolf.com/news-and-events/events>. An archived replay will be available for approximately 90 days following the event.

### About Werewolf Therapeutics:

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.

### Investor Contact:

Josh Rappaport  
Precision AQ  
212.362.1200  
[Josh.Rappaport@precisionaq.com](mailto:Josh.Rappaport@precisionaq.com)

Amanda Sellers  
VERGE Scientific Communications  
301.332.5574  
[asellers@vergescientific.com](mailto:asellers@vergescientific.com)

### Company Contact:

Ellen Lubman  
Chief Business Officer  
Werewolf Therapeutics  
[elubman@werewolf.com](mailto:elubman@werewolf.com)